Summary

Global Anti-Snoring Devices Market Size is estimated to be about USD 0.91 Billion in 2024 and estimated to reach about USD 1.45 Billion by the year 2029, at a growth rate of CAGR of 9.8% during the forecasted period.
The market is projected to expand due to the increasing prevalence of sleep disorders such as sleep apnea, advancements in sleep therapy technologies, and the growing elderly population, which often faces a higher risk of chronic diseases. However, growth may be constrained by the high costs associated with oral sleep appliances and the complexity of referral processes.
Efforts led by government health initiatives and public awareness campaigns addressing sleep disorders are driving market growth further. Moreover, innovations in oral appliance technology and improved comfort features are enhancing patient compliance, encouraging adoption. Despite these positive factors, challenges like expensive devices and complicated diagnostic pathways may slow the growth rate. Nonetheless, the market is set to progress steadily, driven by a stronger focus on sleep health and greater accessibility to advanced treatment solutions.
“The oral appliances segment accounted for the largest share of the market in 2023, by device type.”
The anti-snoring devices market, categorized by device type, includes oral appliances, nasal devices, position control devices, chin straps, and EPAP therapy devices. In 2023, oral appliances held the largest market share, primarily due to the growing popularity of mandibular advancement devices (MADs). This dominance is supported by extensive research demonstrating their superior effectiveness compared to other anti-snoring solutions.
“Home care settings segment dominated the anti-snoring devices market in 2023, based on end user.”
Based on end users, the anti-snoring devices market is segmented into home care settings and hospitals & clinics. The home care settings segment accounted for the largest share of the anti-snoring devices market in 2023. The large share of this segment can be attributed to the increasing patient preference for home sleep testing and the growing number of advanced home sleep care devices available in the market. “Asia Pacific: The fastest-growing region in Anti-snoring devices market.”
The worldwide market for Anti-snoring devices is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. Due to the high prevalence of symptomatic OSA among middle-aged men and women, the anti-snoring devices market in several Asia Pacific countries is expected to witness high growth during the forecast period.
The large patient pool and population of undiagnosed patients indicate a massive potential for the Asia Pacific anti-snoring devices market. The regional and leading players have collaborated, signed several deals, and expanded their presence. Another major growth driver of this segment in the Anti-snoring devices market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the Anti-snoring devices market in the Asia Pacific region.
The break-up of the profile of primary participants in the Anti-snoring devices market:
• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 – 20%
• By Designation: M-level - 30%, D-level - 50%, and Others - 20%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 2%, GCC Countries – 2% (Others-4%)
The key players in this market are are ResMed (US), SomnoMed (Australia), ProSomnus Sleep Technologies (US), and Vivos Therapeutics, Inc. (US), DynaFlex (US), OpenAirway (Canada), Panthera Dental (Canada), Airway Management (US), Apnea Sciences (US), OravanOSA (US), Myerson LLC. (US), Braebon Medical Corporation (Canada), MPowrx Health and Wellness Products (Canada), The Snore Reliever Company, LLC (US), Tomed GmbH (Germany), The Aurum Group (Canada), OSCIMED SA (Switzerland), SICAT GmbH & Co. KG (Germany), Glidewell (US), ApnoMed, Inc. (US), ZQuiet (US), among others.
Research Coverage:
 This research report categorizes the Anti-snoring devices market by device type (Mandibular Advancement Devices, Tongue-retaining Devices, Nasal Devices, Position Control Devices, Chin Straps, EPAP Therapy Devices ), by gender (male, female), by age (below 40, between 40 to 60, above 60), by distribution channel(online, retail, hospital), by end user (home care settings, hospitals & clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the Anti-snoring devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the Anti-snoring devices market. Competitive analysis of upcoming startups in the Anti-snoring devices market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall Anti-snoring devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising incidence of OSA and snoring population, and increased sleep devices technologies ) opportunities (Growth opportunities in emerging economies), restraints (high cost of devices, Unfavorable reimbursement scenario), and challenges (changing regulatory landscape) influencing the growth of the Anti-snoring devices market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the Anti-snoring devices market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Anti-snoring devices market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Anti-snoring devices market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like ResMed (US), SomnoMed (Australia), ProSomnus Sleep Technologies (US), and Vivos Therapeutics, Inc. (US), DynaFlex (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 MARKET SCOPE 31
1.3.1 MARKET SEGMENTATION 31
1.3.2 INCLUSIONS & EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 33
1.3.4 CURRENCY CONSIDERED 33
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key industry insights 39
2.1.2.3 Key data from primary sources 39
2.1.2.4 Breakdown of primary interviews 40
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 41
2.2.1.1 Approach 1: Company revenue estimation approach 41
2.2.1.2 Approach 2: Presentations of companies and primary interviews 42
2.2.1.3 Approach 3: Patient-based approach 42
2.2.1.4 Growth forecast 43
2.2.1.5 CAGR projections 43
2.2.2 TOP-DOWN APPROACH 44
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45
2.4 MARKET SHARE ASSUMPTIONS 46
2.5 STUDY ASSUMPTIONS 46
2.6 RESEARCH LIMITATIONS 46
2.7 RISK ASSESSMENT 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 52
4.1 ANTI-SNORING DEVICES MARKET OVERVIEW 52
4.2 GEOGRAPHIC GROWTH OPPORTUNITIES 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Growing prevalence of sleep disorders 57
5.2.1.2 Increasing geriatric population and subsequent rise in obesity 58
5.2.1.3 Growing cigarette & alcohol consumption 58
5.2.1.4 Rising technological advancements in anti-snoring devices 59
5.2.2 RESTRAINTS 60
5.2.2.1 High price of customized oral appliances 60
5.2.2.2 Unreliable efficacy and inadequate studies for utilization
of anti-snoring devices 60
5.2.2.3 Social stigma associated with snoring 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 Expanding undiagnosed population 61
5.2.3.2 High growth potential of emerging markets 62
5.2.4 CHALLENGES 62
5.2.4.1 Complex referral pathways and long waiting periods 62
5.3 PRICING ANALYSIS 63
5.3.1 AVERAGE SELLING PRICE OF ANTI-SNORING DEVICES, BY KEY PLAYER 63
5.3.2 AVERAGE SELLING PRICE TREND, BY DEVICE TYPE, 2021–2023 64
5.3.3 AVERAGE SELLING PRICE TREND OF ANTI-SNORING DEVICES
(ORAL APPLIANCES), BY REGION, 2021–2023 (USD) 65
5.4 VALUE CHAIN ANALYSIS 65
5.5 SUPPLY CHAIN ANALYSIS 66
5.6 ECOSYSTEM ANALYSIS 67
5.6.1 ANTI-SNORING DEVICES MARKET: ROLE IN ECOSYSTEM 68
5.7 PORTER’S FIVE FORCES ANALYSIS 69
5.7.1 THREAT OF NEW ENTRANTS 70
5.7.2 THREAT OF SUBSTITUTES 70
5.7.3 BARGAINING POWER OF SUPPLIERS 70
5.7.4 BARGAINING POWER OF BUYERS 70
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.8 REGULATORY ANALYSIS 71
5.8.1 REGULATORY LANDSCAPE 71
5.8.1.1 North America 71
5.8.1.1.1 US 71
5.8.1.1.1.1 Reimbursement scenario in US 72
5.8.1.1.2 Canada 73
5.8.1.2 Europe 73

5.8.1.3 Asia Pacific 74
5.8.1.3.1 Japan 74
5.8.1.3.2 China 74
5.8.1.3.3 India 75
5.8.1.3.4 Australia 76
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 76
5.8.2.1 North America 76
5.8.2.2 Europe 77
5.8.2.3 Asia Pacific 77
5.8.2.4 Latin America 78
5.8.2.5 Middle East & Africa 78
5.9 TECHNOLOGY ANALYSIS 79
5.9.1 KEY TECHNOLOGIES 79
5.9.1.1 Mandibular advancement devices 79
5.9.2 ADJACENT TECHNOLOGIES 79
5.9.2.1 Daytime-nighttime appliances 79
5.10 TRADE ANALYSIS 80
5.10.1 IMPORT DATA FOR HS CODE 901849, BY COUNTRY,
2019–2023 (USD MILLION) 80
5.10.2 EXPORT DATA FOR HS CODE 901849, BY COUNTRY,
2019–2023 (USD MILLION) 80
5.11 PATENT ANALYSIS 81
5.12 KEY CONFERENCES & EVENTS, 2024−2025 82
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.14.2 BUYING CRITERIA 84
5.15 IMPACT OF AI/GENERATIVE AI ON ANTI-SNORING DEVICES MARKET 85
5.16 INVESTMENT & FUNDING SCENARIO 85
5.17 CASE STUDY ANALYSIS 86
6 ANTI-SNORING DEVICES MARKET, BY DEVICE TYPE 87
6.1 INTRODUCTION 88
6.2 ORAL APPLIANCES 88
6.2.1 MANDIBULAR ADVANCEMENT DEVICES 93
6.2.1.1 Ready-made mandibular advancement devices 96
6.2.1.1.1 Low cost to fuel uptake 96
6.2.1.2 Custom-made mandibular advancement devices 98
6.2.1.2.1 High efficacy to drive market 98
6.3 TONGUE-RETAINING/STABILIZING DEVICES 101
6.3.1 LOWER SUCCESS RATE OF TRDS TO RESTRAIN MARKET 101

6.4 NASAL DEVICES 103
6.4.1 EXTERNAL NASAL DILATORS 105
6.4.1.1 Convenient and non-invasive benefits to boost demand 105
6.4.2 OTHER NASAL DEVICES 107
6.5 POSITION CONTROL DEVICES 110
6.6 CHIN STRAPS 112
6.7 EPAP THERAPY DEVICES 114
7 ANTI-SNORING DEVICES MARKET, BY GENDER 117
7.1 INTRODUCTION 118
7.2 MALE PATIENTS 119
7.2.1 HIGHER PREVALENCE OF OSA OWING TO ANATOMY VARIATIONS
TO PROPEL MARKET 119
7.3 FEMALE PATIENTS 121
7.3.1 RISING CASES OF UNDIAGNOSED OSA TO DRIVE MARKET 121
8 ANTI-SNORING DEVICES MARKET, BY AGE GROUP 123
8.1 INTRODUCTION 124
8.2 BELOW 40 YEARS 125
8.2.1 LOW PREVALENCE OF OSA AMONG YOUNGER INDIVIDUALS
TO RESTRAIN MARKET 125
8.3 BETWEEN 40–60 YEARS 127
8.3.1 INCREASING INCIDENCE OF CVD AND HYPERTENSION TO PROPEL MARKET 127
8.4 ABOVE 60 YEARS 129
8.4.1 CHANGING SLEEPING PATTERNS TO SUPPORT MARKET GROWTH 129
9 ANTI-SNORING DEVICES MARKET, BY DISTRIBUTION CHANNEL 132
9.1 INTRODUCTION 133
9.2 ONLINE PHARMACIES 133
9.2.1 GROWING PREFERENCE FOR DIRECT DISTRIBUTION CHANNELS TO DRIVE MARKET 133
9.3 RETAIL PHARMACIES 136
9.3.1 CONVENIENT ACCESSIBILITY TO PRODUCTS TO PROPEL MARKET 136
9.4 HOSPITAL PHARMACIES 138
9.4.1 GROWING FOCUS ON PATIENT CONVENIENCE TO FUEL UPTAKE 138
10 ANTI-SNORING DEVICES MARKET, BY END USER 140
10.1 INTRODUCTION 141
10.2 HOME CARE SETTINGS 141
10.2.1 GROWING PATIENT PREFERENCE FOR ADVANCED SLEEP MONITORING DEVICES TO PROPEL MARKET 141
10.3 HOSPITALS & CLINICS 143
10.3.1 RAPID DEVELOPMENT IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET 143
11 ANTI-SNORING DEVICES MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 148
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 148
11.2.2 US 153
11.2.2.1 Rising trend of remote sleep testing to fuel uptake 153
11.2.3 CANADA 157
11.2.3.1 Increasing number of research grants for sleep apnea devices to boost demand 157
11.3 EUROPE 160
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 161
11.3.2 GERMANY 164
11.3.2.1 High prevalence of smoking to boost demand 164
11.3.3 UK 168
11.3.3.1 Rising awareness and increasing number of sleep service groups to support market growth 168
11.3.4 FRANCE 171
11.3.4.1 Rising geriatric population to fuel uptake 171
11.3.5 ITALY 175
11.3.5.1 Favorable initiatives for treatment of OSA to support market growth 175
11.3.6 SPAIN 178
11.3.6.1 Increasing initiatives for social awareness by regional organizations for treatment to drive market 178
11.3.7 REST OF EUROPE 181
11.4 ASIA PACIFIC 185
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 185
11.4.2 CHINA 190
11.4.2.1 Growing adult obesity rates and expanding geriatric population to propel market 190
11.4.3 JAPAN 193
11.4.3.1 Rising demand for cloud-connected OSA therapy devices to boost demand 193
11.4.4 AUSTRALIA 196
11.4.4.1 Rising R&D initiatives for innovative sleep therapy devices to boost demand 196
11.4.5 REST OF ASIA PACIFIC 199
11.5 LATIN AMERICA 203
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 203
11.5.2 BRAZIL 207
11.5.2.1 Favorable reimbursement policies for advanced sleep apnea procedures to drive market 207
11.5.3 MEXICO 210
11.5.3.1 Poor healthcare infrastructure to limit market growth 210
11.5.4 REST OF LATIN AMERICA 213
11.6 MIDDLE EAST & AFRICA 216
11.6.1 PRESENCE OF GLOBAL PLAYERS AND HIGH INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 216
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 217
11.7 GCC COUNTRIES 220
11.7.1 HIGH OBESITY RATES TO SUPPORT MARKET GROWTH 220
11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 221
12 COMPETITIVE LANDSCAPE 225
12.1 OVERVIEW 225
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 225
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTI-SNORING DEVICES MARKET 225
12.3 REVENUE ANALYSIS, 2019–2023 227
12.4 MARKET SHARE ANALYSIS, 2023 228
12.4.1 RANKING OF KEY MARKET PLAYERS 230
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 230
12.5.1 STARS 230
12.5.2 EMERGING LEADERS 230
12.5.3 PERVASIVE PLAYERS 230
12.5.4 PARTICIPANTS 230
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 232
12.5.5.1 Company footprint 232
12.5.5.2 Region footprint 233
12.5.5.3 Device footprint 234
12.5.5.4 Distribution channel footprint 234
12.5.5.5 End-user footprint 235
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 235
12.6.1 PROGRESSIVE COMPANIES 235
12.6.2 RESPONSIVE COMPANIES 235
12.6.3 DYNAMIC COMPANIES 236
12.6.4 STARTING BLOCKS 236
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 237
12.7 COMPANY VALUATION & FINANCIAL METRICS 238
12.7.1 FINANCIAL METRICS 238
12.7.2 COMPANY VALUATION 238
12.8 BRAND/PRODUCT COMPARISON 239
12.9 COMPETITIVE SCENARIO 240
12.9.1 PRODUCT LAUNCHES & APPROVALS 240
12.9.2 DEALS 241
12.9.3 EXPANSIONS 242
12.9.4 OTHER DEVELOPMENTS 242
13 COMPANY PROFILES 243
13.1 KEY PLAYERS 243
13.1.1 RESMED 243
13.1.1.1 Business overview 243
13.1.1.2 Products offered 245
13.1.1.3 Recent developments 245
13.1.1.3.1 Deals 245
13.1.1.3.2 Expansions 246
13.1.1.4 MnM view 246
13.1.1.4.1 Key strengths 246
13.1.1.4.2 Strategic choices 246
13.1.1.4.3 Weaknesses & competitive threats 246
13.1.2 SOMNOMED 247
13.1.2.1 Business overview 247
13.1.2.2 Products offered 248
13.1.2.3 MnM view 248
13.1.2.3.1 Key strengths 248
13.1.2.3.2 Strategic choices 248
13.1.2.3.3 Weaknesses & competitive threats 248
13.1.3 PROSOMNUS SLEEP TECHNOLOGIES 249
13.1.3.1 Business overview 249
13.1.3.2 Products offered 250
13.1.3.3 Recent developments 250
13.1.3.3.1 Deals 250
13.1.3.4 MnM view 250
13.1.3.4.1 Key strengths 250
13.1.3.4.2 Strategic choices 250
13.1.3.4.3 Weaknesses & competitive threats 251
13.1.4 VIVOS THERAPEUTICS, INC. 252
13.1.4.1 Business overview 252
13.1.4.2 Products offered 253
13.1.4.3 Recent developments 253
13.1.4.3.1 Product approvals 253
13.1.4.3.2 Deals 253
13.1.4.3.3 Expansions 254
13.1.4.3.4 Other developments 254
13.1.5 DYNAFLEX 255
13.1.5.1 Business overview 255
13.1.5.2 Products offered 255
13.1.5.3 Recent developments 256
13.1.5.3.1 Deals 256

13.1.6 OPENAIRWAY 257
13.1.6.1 Business overview 257
13.1.6.2 Products offered 257
13.1.6.3 Recent developments 257
13.1.6.3.1 Deals 257
13.1.7 PANTHERA DENTAL 258
13.1.7.1 Business overview 258
13.1.7.2 Products offered 258
13.1.7.3 Recent developments 258
13.1.7.3.1 Product launches 258
13.1.7.3.2 Deals 259
13.1.7.3.3 Other developments 259
13.1.8 AIRWAY MANAGEMENT 260
13.1.8.1 Business overview 260
13.1.8.2 Products offered 260
13.1.8.3 Recent developments 260
13.1.8.3.1 Product launches 260
13.1.9 APNEA SCIENCES 261
13.1.9.1 Business overview 261
13.1.9.2 Products offered 261
13.1.10 ORAVANOSA 262
13.1.10.1 Business overview 262
13.1.10.2 Products offered 262
13.1.11 MYERSON LLC 263
13.1.11.1 Business overview 263
13.1.11.2 Products offered 263
13.1.12 BRAEBON MEDICAL CORPORATION 264
13.1.12.1 Business overview 264
13.1.12.2 Products offered 264
13.2 OTHER PLAYERS 265
13.2.1 MPOWRX HEALTH & WELLNESS PRODUCTS 265
13.2.2 THE SNORE RELIEVER COMPANY, LLC 265
13.2.3 TOMED GMBH 266
13.2.4 THE AURUM GROUP 266
13.2.5 OSCIMED SA 267
13.2.6 SICAT GMBH & CO. KG 267
13.2.7 GLIDEWELL 268
13.2.8 APNOMED, INC. 269
13.2.9 ZQUIET 269
13.2.10 DREAM SYSTEMS DENTAL SLEEP LAB 270

13.2.11 PURE SLEEP COMPANY 270
13.2.12 THERAVENT, INC. 271
13.2.13 INNOVATIVE HEALTH TECHNOLOGIES 271
14 APPENDIX 272
14.1 DISCUSSION GUIDE 272
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 276
14.3 CUSTOMIZATION OPTIONS 278
14.4 RELATED REPORTS 278
14.5 AUTHOR DETAILS 279